Appendix 4C - Quarterly - 30 June 2026
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights the appointment of CMAX as the clinical trial site and Alithia Life Sciences as the Contract Research Organisation, marking key operational milestones achieved during the quarter. Additionally, the company successfully completed a capital placement to support its clinical and regulatory activities, strengthening its financial position ahead of the trial initiation. The report indicates that first participant dosing is targeted for the upcoming quarter, pending necessary approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Appendix 4C - Quarterly - 31 March 2026
- $3.2 million Placement to Advance Clinical Trials
- Investor Presentation - Broker Meets Biotech
Later from Patrys
- Investor Presentation - TechKnow Invest Roadshow
- Ethics Approval Secured for Phase 1A Clinical Trial
- PAB Establishes Clinical Advisory Committee
- First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
- Appendix 4E Variance Report
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys